Abbott

Abbott Laboratories launches a high-protein shake to help people maintain muscle mass while pursuing weight loss, one of a wave of such products expected to come to market amid strong demand for new weight-loss drugs. Companies including Abbott and Nestle have said in recent months that they would develop companion products for people trying to shed pounds. Abbott’s shake, introduced under the company’s new Protality brand, is intended for adults who may have a hard time getting enough protein and other essential nutrients to support muscle mass while consuming fewer calories, the company says. Marketed in milk chocolate and vanilla flavors, it will be sold online and in stores like Walmart and Kroger, Abbott says.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target price to $113 from $130, 24.4x our ’24 EPS forecast, in line with ABT’s historical forward average. We lift our ’23 EPS estimate by $0.03 to $4.43 and maintain our ’24 estimate of $4.63. Q3 adj. EPS of $1.14 vs. $1.15 beat the consensus view by $0.04, driven by sales growth from Nutrition (+16% Y/Y) due to continued market share recapture in the U.S. infant formula business, where ABT has now reclaimed the leadership position, in addition to growth in Medical Device sales (+17% Y/Y), aided by FreeStyle Libre sales growth of 28% in Q3. ABT sees a growing number of Libre users in the U.S. using Libre in combination with GLP-1 medications — a view that these approaches are complementary as

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target price to $113 from $130, 24.4x our ’24 EPS forecast, in line with ABT’s historical forward average. We lift our ’23 EPS estimate by $0.03 to $4.43 and maintain our ’24 estimate of $4.63. Q3 adj. EPS of $1.14 vs. $1.15 beat the consensus view by $0.04, driven by sales growth from Nutrition (+16% Y/Y) due to continued market share recapture in the U.S. infant formula business, where ABT has now reclaimed the leadership position, in addition to growth in Medical Device sales (+17% Y/Y), aided by FreeStyle Libre sales growth of 28% in Q3. ABT sees a growing number of Libre users in the U.S. using Libre in combination with GLP-1 medications — a view that these approaches are complimentary as

Abbott Projects FY23 Adjusted EPS Of $4.42-$4.46 Versus Prior Guidance Of $4.30-$4.50 And Consensus Of $4.18.

ABBOTT Posts Q3 EPS $1.14, vs. Street Est of $1.10。

The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share. This marks the 399(th) consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2023, to shareholders of record at the close of business on Oct. 13, 2023. Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.

Abbott Laboratories (NYSE:ABT) To Acquire Bigfoot Biomedical, Furthering Efforts To Develop Personalized, Connected Solutions For People With Diabetes。

Abbott Laboratories (NYSE:ABT) reported Q2 adjusted earnings Thursday of $1.08 per diluted share, down from $1.43 a year earlier. Analysts polled by Capital IQ expected adjusted EPS of $1.05. Net sales for the quarter ended June 30 were $9.98 billion, down from $11.26 billion a year earlier. Analysts surveyed by Capital IQ expected $9.72 billion. For the full-year 2023, the company reaffirmed its adjusted EPS guidance of $4.30 to $4.50. Analysts surveyed by Capital IQ expect $4.40.

Shares rose 47 percent to $19.58 in early trading after Abbott (NYSE:ABT) agreed to buy Cardiovascular Systems (CSII) for $890 million, or $20 per share, MarketWatch reported. Termao Cardiovascular Systems is a leader in percutaneous atherectomy of transluminal plaques, a minimally invasive treatment for plaque buildup in the arteries. Abbott said the deal’s impact on its recently issued 2023 EPS guidance is neutral.